ClinicalTrials.gg
TerminatedNCT02914600DIVERSITY LTEUpdated Jul 10, 2024Results posted

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

A Phase 3 interventional study of Filgotinib and Placebo in Crohn's Disease, sponsored by Galapagos NV. Terminated at 487 sites in 40 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by Galapagos NV · Phase 3, Interventional, and Treatment

Why this study was terminated
development program for filgotinib for participants with Crohn's disease has been stopped

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,188
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
13th of 528
1,188 · median 60
Started
2017
with 36 others
Phase 3
124 of 660
21 open now
Registered
326th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 13th largest by enrollment of the 528 interventional ones that give a count, is one of 37 that started in 2017, is one of 124 in phase 3, and was the 326th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have the ability to understand and sign a written form (ICF), which must be obtained prior to initiation of study procedures associated with this trial
  • Must have enrolled in a CD parent protocol, GS-US-419-4015, GS-US-419-4016 or GS-US-419-3895 or any other Gilead/Galapagos sponsored filgotinib treatment study for CD
  • Females of must have a negative pregnancy test at Day 1 and must agree to continued monthly pregnancy testing during use of filgotinib treatment
  • Female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of for the duration described in the protocol
  • Willingness to refrain from live or attenuated vaccines during the study and for 12 weeks after last dose of study drug
  • Must have completed all required procedures or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study for CD

Key Exclusion Criteria:

  • Known to the study drug
  • Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease, alcohol or drug abuse) that, in the opinion of the Investigator or sponsor, would make the individual unsuitable for the study or would prevent compliance with the study protocol
  • Females of who are unwilling to abide by protocol-specified contraceptive methods as defined in the protocol
  • Use of prohibited concomitant medications as outlined in the study protocol

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,188 participants (actual)

Study arms

  • Experimental
    Filgotinib 200 mg

    Participants who received filgotinib 200 milligrams (mg) blinded and completed the parent study, continued to receive filgotinib 200 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 200 mg. Participants who exited the parent study due to disease worsening or failure to meet response or remission criteria, with the exception of US and Korean males who were not considered dual-biologic refractory, received filgotinib 200 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).

    Drug: Filgotinib

  • Experimental
    Filgotinib 100 mg

    Participants who received filgotinib 100 mg blinded and completed the parent study, continued to receive filgotinib 100 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 100 mg. Male participants from the US \& Korea who were not considered dual biologic refractory, and who exited the parent study due to disease worsening or failure to meet response or remission criteria, received filgotinib 100 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).

    Drug: Filgotinib

  • Placebo comparator
    Placebo

    Participants who received placebo and completed the parent study, continued to receive placebo in this extension study. After unblinding of the parent study, participants on placebo treatment discontinued study drug and study participation. Treatment was administered orally once a day until unblinding of the parent study (up to 308 weeks).

    Drug: Placebo

Interventions

  • Tablet administered orally once a day

    Also known as: GS-6034, GLPG0634, Jyseleca®

  • DrugPlacebo

    Tablet administered orally once a day

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a participant administered a study drug, and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug whether or not considered related to the study drug. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug.

    Time frame: From the First Dose to Week 312

Secondary outcomes

  1. Change From Baseline in Patient Reported Outcomes 2 (PRO2) Scores for Liquid or Very Soft Stools

    The PRO2 was a composite score based on 2 components of CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain) assessed for 7 days. The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4, higher values mean worse well-being), and number of liquid or very soft stools were summed over the 7 days prior to each visit. The remaining predictors were also weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Change from baseline for number of liquid or very soft stool per day was reported.

    Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300

  2. Change From Baseline in Patient Reported Outcomes (PRO2) Scores for Abdominal Pain

    The PRO2 was a composite score based on 2 components of CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain) assessed for 7 days. The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4, higher values mean worse well-being), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Change from baseline in abdominal pain was reported.

    Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300

  3. Change From Baseline in CDAI Scores

    The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain), general well-being (0-4, higher values mean worse well-being), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.

    Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300

07

Results

Posted Jul 10, 2024
Limitations and caveats
The results of DIVERSITY 1 study with filgotinib in participants with moderate to severely active CD failed to meet the co-primary endpoints of clinical remission and endoscopic response for filgotinib 100 mg q.d. and 200 mg q.d. in the study. After analyzing all available data from the DIVERSITY 1 and DIVERSITY long term extension (LTE) studies, the sponsor decided not to pursue extension of the filgotinib indication for CD and decided to terminate the DIVERSITY LTE study.

Participant flow

Participants were enrolled at study sites in 37 countries: Australia, Austria, Belgium, Canada, Croatia, Czech Republic, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, the Netherlands, New-Zealand, Poland, Portugal, Republic of Korea, Romania, Russia, Serbia, Singapore, Slovakia, South-Africa, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Ukraine, the United Kingdom, and the United States (US).

Participant flow — Overall Study
MilestoneFilgotinib 200 mgFilgotinib 100 mgPlacebo
Started945119124
Treated944119124
Completed000
Not completed945119124
Withdrew: Adverse event2983525
Withdrew: Sponsors decision2874112
Withdrew: Withdrawal by subject1582018
Withdrew: Investigators discretion1691413
Withdrew: Lost to follow-up1040
Withdrew: Pregnancy800
Withdrew: Protocol violation530
Withdrew: Non-compliance with study drug610
Withdrew: Death311
Withdrew: Current study unblinded and participant confirmed on placebo0055
Withdrew: Enrolled but not treated100

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant administered a study drug, and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug whether or not considered related to the study drug. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug.

Time frame:
From the First Dose to Week 312
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Number of Participants With Treatment Emergent Adverse Events (TEAEs)82010396
SecondaryChange From Baseline in Patient Reported Outcomes 2 (PRO2) Scores for Liquid or Very Soft Stools

The PRO2 was a composite score based on 2 components of CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain) assessed for 7 days. The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4, higher values mean worse well-being), and number of liquid or very soft stools were summed over the 7 days prior to each visit. The remaining predictors were also weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Change from baseline for number of liquid or very soft stool per day was reported.

Time frame:
Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Reported as:
Mean · Number of liquid/very soft stools/day
Change From Baseline in Patient Reported Outcomes 2 (PRO2) Scores for Liquid or Very Soft Stools
Number of liquid/very soft stools/dayFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline5.6 ± 3.264.0 ± 3.122.2 ± 1.92
Change at Week 12-1.6 ± 2.71-0.7 ± 2.010.2 ± 1.44
Change at Week 24-1.8 ± 2.89-0.7 ± 2.590.1 ± 1.15
Change at Week 48-2.0 ± 3.14-0.8 ± 2.490.0 ± 1.21
Change at Week 96-2.2 ± 3.11-0.7 ± 2.700.4 ± 2.79
Change at Week 156-2.4 ± 3.14-0.7 ± 3.19-0.2 ± 1.63
Change at Week 216-2.8 ± 3.17-1.2 ± 4.101.0 ± 1.41
Change at Week 264-2.0 ± 2.86-4.8 ± 6.18—
Change at Week 3000.0 ± 2.71——
SecondaryChange From Baseline in Patient Reported Outcomes (PRO2) Scores for Abdominal Pain

The PRO2 was a composite score based on 2 components of CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain) assessed for 7 days. The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4, higher values mean worse well-being), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Change from baseline in abdominal pain was reported.

Time frame:
Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Reported as:
Mean · units on a scale
Change From Baseline in Patient Reported Outcomes (PRO2) Scores for Abdominal Pain
units on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline1.6 ± 0.911.0 ± 0.890.7 ± 0.75
Change at Week 12-0.6 ± 0.91-0.2 ± 0.650.0 ± 0.52
Change at Week 24-0.7 ± 0.92-0.2 ± 0.750.0 ± 0.51
Change at Week 48-0.8 ± 0.97-0.3 ± 0.70-0.1 ± 0.54
Change at Week 96-0.8 ± 1.00-0.2 ± 0.730.0 ± 0.55
Change at Week 156-0.8 ± 0.98-0.2 ± 0.770.0 ± 0.57
Change at Week 216-0.9 ± 1.05-0.5 ± 0.880.0 ± 0.00
Change at Week 264-0.8 ± 0.64-1.3 ± 0.50—
Change at Week 300-0.3 ± 0.50——
SecondaryChange From Baseline in CDAI Scores

The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain), general well-being (0-4, higher values mean worse well-being), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.

Time frame:
Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Reported as:
Mean · units on a scale
Change From Baseline in CDAI Scores
units on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline280.5 ± 116.58189.9 ± 112.73120.4 ± 81.33
Change at Week 12-86.8 ± 114.02-29.1 ± 79.844.2 ± 53.42
Change at Week 24-98.5 ± 122.68-30.8 ± 92.925.7 ± 51.30
Change at Week 48-110.2 ± 125.08-40.9 ± 91.470.6 ± 49.32
Change at Week 96-118.6 ± 131.49-23.3 ± 91.9411.0 ± 69.29
Change at Week 156-121.4 ± 132.33-33.5 ± 99.150.3 ± 59.27
Change at Week 216-137.0 ± 147.14-57.5 ± 121.122.5 ± 37.76
Change at Week 264-134.8 ± 128.86-171.5 ± 141.81—
Change at Week 300-32.5 ± 92.99——

Adverse events

Collected over From the First Dose to Week 312. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Filgotinib 200 mg6/944 (0.6%)284/944 (30.1%)697/944 (73.8%)
Filgotinib 100 mg2/119 (1.7%)34/119 (28.6%)89/119 (74.8%)
Placebo1/124 (0.8%)20/124 (16.1%)78/124 (62.9%)
Most frequent serious events
Showing 10 of 207
Most frequent serious events
EventFilgotinib 200 mgFilgotinib 100 mgPlacebo
Crohn's diseaseGastrointestinal disorders101/9445/1194/124
Small intestinal obstructionGastrointestinal disorders11/9449/1193/124
Abdominal painGastrointestinal disorders17/9442/1190/124
Intestinal obstructionGastrointestinal disorders8/9442/1190/124
Anal abscessInfections and infestations15/9440/1190/124
Lip and/or oral cavity cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/9441/1190/124
Papillary renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/9441/1190/124
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/9441/1190/124
Abortion spontaneousPregnancy, puerperium and perinatal conditions2/9441/1190/124
Condition aggravatedGeneral disorders0/9441/1190/124
Most frequent other events
Showing 10 of 59
Most frequent other events
EventFilgotinib 200 mgFilgotinib 100 mgPlacebo
Crohn's diseaseGastrointestinal disorders210/94426/11920/124
COVID-19Infections and infestations127/94417/1199/124
Abdominal painGastrointestinal disorders93/94415/11915/124
ArthralgiaMusculoskeletal and connective tissue disorders82/94415/1191/124
NasopharyngitisInfections and infestations81/94413/1196/124
HeadacheNervous system disorders79/9444/11911/124
DiarrhoeaGastrointestinal disorders54/94410/11911/124
NauseaGastrointestinal disorders74/9448/1194/124
VomitingGastrointestinal disorders67/9443/1193/124
PyrexiaGeneral disorders65/9443/1190/124

Baseline characteristics

Safety analysis set included all participants who took at least 1 dose of study drug in this study.

Age, Continuous
Age, Continuous(years)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Mean39 ± 13.6047 ± 13.2842 ± 12.4240 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Female5143356603
Male4308668584
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Hispanic or Latino185023
Not Hispanic or Latino9041121231139
Unknown or Not Reported222125
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
American Indian or Alaska Native1001
Asian1371823178
Native Hawaiian or Other Pacific Islander2002
Black or African American1810331
White7398996924
More than one race0000
Unknown or Not Reported472251
08

Study locations

487 sites
  • Digestive Health Specialists Of The Southeast
    Dothan, Alabama 36305, United States
  • Arizona Digestive Health - Sun City
    Sun City, Arizona 85351, United States
  • Southern California Research Center, Inc.
    Coronado, California 92118, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Inland Empire Clinical Trials, LLC
    Rialto, California 92377, United States
  • UC San Diego Health Systems
    San Diego, California 92093, United States
  • Kaiser Permanente
    San Francisco, California 94118, United States
  • Clearview Medical Research, LLC
    Santa Clarita, California 91351, United States
  • University of Colorado Denver and Hospital
    Aurora, Colorado 80045, United States
  • South Denver Gastroenterology, PC
    Lone Tree, Colorado 80124, United States
  • Connecticut GI, PC - Research Division
    Farmington, Connecticut 06032, United States
  • Medstar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Advanced Research, LLC
    Coral Springs, Florida 33067, United States
  • UF Clinical Research Center
    Gainesville, Florida 32610, United States
  • Florida Research Institute
    Lakewood Ranch, Florida 34211, United States
  • Florida Center for Gastroenterology
    Largo, Florida 33777, United States
  • University of Miami Crohn's and Colitis Center
    Miami, Florida 33136, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • Cordova Research Institute
    Miami, Florida 33155, United States
  • Vista Health Research, LLC
    Miami, Florida 33176, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Center for Interventional Endoscopy - Florida Hospital
    Orlando, Florida 32803, United States
  • Gulf Region Clinical Research Institute
    Pensacola, Florida 32514, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Florida Medical Clinic, P.A
    Zephyrhills, Florida 33540, United States
  • Gastroenterology Associates Of Central Georgia, LLC
    Macon, Georgia 31201, United States
  • Gastrointestinal Specialists of Georgia
    Marietta, Georgia 30060, United States
  • Atlanta Gastroenterology Specialist, PC
    Suwanee, Georgia 30024, United States
  • Illinois Gastroenterology Group - Arlington Heights
    Arlington Heights, Illinois 60005, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • The University of Chicago Medical Center (Clinic)
    Chicago, Illinois 60637, United States
  • Illinois Gastroenterology Group - Gurnee
    Gurnee, Illinois 60031, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Louisville, Clinical Trials Unit
    Louisville, Kentucky 40202, United States
  • Delta Research Partners, LLC
    Monroe, Louisiana 71201, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Investigative Clinical Research
    Annapolis, Maryland 21401, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • MGG Group Co., Inc., Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Gastro Center of Maryland
    Columbia, Maryland 21045, United States
  • Meritus Center for Clinical Research
    Hagerstown, Maryland 21742, United States
  • Massachusetts General Hospital - Crohn's and Colitis Center
    Boston, Massachusetts 02114, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Spectrum Health Butterworth Hospital
    Grand Rapids, Michigan 49546, United States
  • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center
    Wyoming, Michigan 49519, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89113, United States
  • AGA Clinical Research Associates, LLC
    Egg Harbor Township, New Jersey 08234, United States
  • NY Scientific
    Brooklyn, New York 11235, United States
  • NYU Langone Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • New York University School of Medicine / NYU Gastroenterology Associates
    New York, New York 10016, United States
  • Lenox Hill Hospital
    New York, New York 10028, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Premier Medical Group of the Hudson Valley
    Poughkeepsie, New York 12601, United States
  • Charlotte Gastroenterology & Hepatology, PLLC
    Charlotte, North Carolina 28207, United States
  • Carolina's GI Research LLC
    Raleigh, North Carolina 27607, United States
  • Fargo Gastroenterology and Hepatology Clinic
    Fargo, North Dakota 58103, United States
  • Consultants for Clinical Research
    Cincinnati, Ohio 45219, United States
  • UC Health Physicians Clifton
    Cincinnati, Ohio 45219, United States
  • Great Lakes Gastroenterology Research, LLC
    Mentor, Ohio 44060, United States
  • Paramount Medical Research & Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • Options Health Research LLC
    Tulsa, Oklahoma 74104, United States
  • Great Lakes Medical Research, LLC
    Harrisburg, Pennsylvania 17110, United States
  • Gastroenterology Associates of Orangeburg
    Orangeburg, South Carolina 29118, United States
  • WR-ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Quality Medical Research
    Nashville, Tennessee 37211, United States
  • Vanderbilt University Medical Center - IBD Clinic
    Nashville, Tennessee 37212, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • Pinnacle Clinical Research
    Austin, Texas 78757, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • San Antonio Military Medical Center,
    Fort Sam Houston, Texas 78219, United States
  • DHAT Research Institute
    Garland, Texas 75044, United States
  • Kelsey-Seybold Clinic
    Houston, Texas 77025, United States
  • Baylor College of Medicine - McNair Campus
    Houston, Texas 77030, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Centex Studies, Inc.
    Houston, Texas 77058, United States
  • Gulf Coast Research Group
    Houston, Texas 77098, United States
  • Clinical Associates in Research Therapeutics of America, LLC
    San Antonio, Texas 78212, United States
  • Gastroenterology Research of San Antonio
    San Antonio, Texas 78229, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
  • TDDC San Marcos
    San Marcos, Texas 78666, United States
  • Texas Digestive Disease Consultants
    Southlake, Texas 76092, United States
  • Spring Gastroenterology
    The Woodlands, Texas 77380, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
  • HP Clinical Research
    Bountiful, Utah 84010, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Charlottesville Medical Research Center, LLC
    Charlottesville, Virginia 22911, United States
  • Gastroenterology Associates of Tidewater
    Chesapeake, Virginia 23320, United States
  • McGuire DVAMC
    Richmond, Virginia 23249, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • University of Wisconsin Hospital & Clinics
    Madison, Wisconsin 53705, United States
  • Wisconsin Center for Advanced Research, a division of GI Associates, LLC
    Milwaukee, Wisconsin 53215, United States

Showing the first 100 of 487 sites across 40 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Aug 2023, 76 months.

Results were first posted in Jul 2024, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2016
First posted
Sep 26, 2016
StartActual
Mar 17, 2017
Primary completionActual
Aug 1, 2023
CompletionActual
Aug 1, 2023
Results first posted
Jul 10, 2024
Last update
Jul 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02914600
Lead sponsor
Galapagos NV
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 26, 2016
Start date
Mar 17, 2017
Primary completion
Aug 1, 2023
Completion
Aug 1, 2023
Results posted
Jul 10, 2024
Last update
Jul 10, 2024

Study contacts

Galapagos Study Director
study director · Galapagos NV

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion